EUVIMEDEUVIMED entdecken
Crossref

Repurposing FDA‐approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach

Kanika Verma, Rini Chaturvedi, Ayush K Lahariya, Anil K Verma, Kristan A Schneider, Anup R Anvikar, Praveen K Bharti iD

Journal of Cellular Biochemistry · 2024

DOI: 10.1002/jcb.30533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2024. Verfasst von Kanika Verma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Epidemiology, National Institute of Malaria Research, New Delhi, India. Hauptthemen laut MEDLINE: Antimalarials, Malaria, Folic Acid Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Indian Council of Medical Research, Bundesministerium für Bildung und Forschung (BMBF), Department of Science and Technology (DST).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dihydrofolate reductase (DHFR) is a ubiquitous enzyme that regulates the biosynthesis of tetrahydrofolate among various species of Plasmodium parasite. It is a validated target of the antifolate drug pyrimethamine (Pyr) in Plasmodium falciparum ( Pf ), but its clinical efficacy has been hampered due to the emergence of drug resistance. This has made the attempt to screen Food & Drug Administration‐approved drugs against wild‐ and mutant Pf DHFR by employing an in‐silico pipeline to identify potent candidates. The current study has followed a virtual screening approach for identifying potential DHFR inhibitors from DrugBank database, based on a structure similarity search of candidates, followed by absorption, distribution, metabolism, and excretion estimation. The screened drugs were subjected to various parameters like docking, molecular mechanics with generalized born and surface area solvation calculations, and molecular simulations. We have thus identified two potential drug candidates, duloxetine and guanethidine, which can be repurposed to be tested for their efficacy against wild type and drug resistant falciparum malaria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsMalariaFolic Acid AntagonistsHumansTetrahydrofolate DehydrogenasePharmaceutical PreparationsDrug RepositioningDrug ResistanceFolic Acid

Stichwörter der Autor:innen

dihydrofolate reductase (DHFR)drug resistancemolecular dockingmolecular simulationrepurposing

Substanzen

AntimalarialsTetrahydrofolate DehydrogenasePharmaceutical PreparationsFolic Acid AntagonistsFolic Acid

Autor:innen und Institutionen

  • Department of Molecular Epidemiology, National Institute of Malaria Research, New Delhi, India.
  • Structural Parasitology Lab, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
  • Division of Vector-Borne Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
  • Department Applied Computer and Bio-Sciences, University of Applied Sciences, Mittweida, Germany.

ORCID-Profile: Praveen K Bharti

Förderung

  • Indian Council of Medical Research
  • Bundesministerium für Bildung und Forschung (BMBF)
  • Department of Science and Technology (DST)

Zitieren

APA

Verma, K., Chaturvedi, R., Lahariya, A. K., Verma, A. K., Schneider, K. A., Anvikar, A. R., & Bharti, P. K. (2024). Repurposing FDA‐approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.30533

Vancouver

Verma K, Chaturvedi R, Lahariya AK, Verma AK, Schneider KA, Anvikar AR, et al. Repurposing FDA‐approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach. Journal of Cellular Biochemistry. 2024. doi:10.1002/jcb.30533

BibTeX
@article{Verma2024,
  author = {Verma, Kanika and Chaturvedi, Rini and Lahariya, Ayush K and Verma, Anil K and Schneider, Kristan A and Anvikar, Anup R and Bharti, Praveen K},
  title = {Repurposing FDA‐approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach},
  journal = {Journal of Cellular Biochemistry},
  year = {2024},
  doi = {10.1002/jcb.30533}
}
Kostenlos starten →